Latest Content

The agency assigned a PDUFA target action date of April 30, 2027.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management.

The company announced phase 2 results of a dual-action lifitegrast/perfluorohexyloctane dry eye drop alongside positive phase 1b results for BL1332, a first-in-class TRPV1 antagonist for ocular surface pain.

Teacher-led vision screening identified about 3 in 4 children with refractive error and correctly cleared most unaffected students.

The FDA has expanded the indication to include improvement of meibomian gland function in adult patients with evaporative dry eye disease due to MGD, making it the first treatment with this indication.

This review summarizes major contact lens risks, solution-related adverse effects, higher-risk populations, and practical prevention strategies for optometric practice.

Catch up on the top stories in optometry during the week of August 17-21.

Perceived stress modestly predicted later dry eye symptoms in young adults, but significance depended on a prespecified 1-tailed test.

The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Recommending omega-3 fatty acids in the diet of a patient with DED could lead to improved tear osmolarity and tear breakup time and thus fewer dry eye symptoms.

Phase 3 Duravyu insert misses key vision end point in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

Corrected presbyopes used larger fonts, held smartphones farther away, and read more slowly, suggesting 40-cm testing may miss device demands.